乌司他丁对急性肺损伤／急性呼吸窘迫综合征治疗效果分析

目的：探讨乌司他丁（ulinastatin，UTI）对急性肺损伤，急性呼吸窘迫综合征（acute lung injury／acute respiratory distress。ALI／ARDS）的治疗效果。方法：ALI／ARDS患者40例，随机分为UTI治疗组（n=20）和对照组（n=20）；对照组接受常规治疗，UTI治疗组在常规治疗基础上静脉推注乌司他丁20万u，每8h1次，连用10天。观察两组的临床疗效、治疗前后心率、呼吸、动脉血气以及血清肿瘤坏死因子-a（TNF-a）、IL-6水平变化。结果：治疗组有效率90．0％，明显高于对照纽65．0％（x2=3．856，P〈0．05）；两组治疗前后各项指标比较均有统计学差并（t=2．231、2．311、2.215、2．301、2．315、2．333、2．341、2．401、2．451、2．342、2．332、2．333，P均〈0．05）；两组治疗8d，PaO2、心率、呼吸、有显著性差异（t=2．232、2．311、2．3415，P均〈0．05）；两组治疗前后TNF—a、IL-6含量差异有统计学意义（t=2．378、2．431、2．331、2．322，P均〈0．05），结论：乌司他丁减轻炎性反应对机体的损伤，改善AIMARDS的预后。

Curative effect of ulinastatin on acute lung injury/acute respiratory distress

Objective To investigate the curative effect of ulinastatin on acute lung injury/acute respiratory distress syndrome（ALI/ARDS）.Methods 40 patients with ALI/ARDS were randomly divided into treatment group （n=20）and control group （n= 20）.The control group received only the routine therapy, and the treatment group were given ulinastatin（200 ku intravenously, once every 8 hours, and continued for 10 days） in addition to the routine treatment.The Methods：Thirty-four patients with ALI/ARDSwere randomly divided into treatment group（n=17） and control group （n=17）. The control group received only the routine therapy, and the treatment group were given ulinastatin （200 ku intravenously,once every 8 hours, and continued for 10 days） in addition to the routine treatment.The index of clinical efficacy,heart rate,breathing, arterial blood gas,serum tumor necrosis factor-or （TNF-a）.Interleukin -6 （IL-6） before treatment and after treatment were observed.Results The effet rate 90.0% in treatment group were significantly higher than 65.0% in control group （X2=3.856,P〈0.05）;The projects Comparative before and after treatment in both groups were statistically significant （t=2.231,2.311,2.215,2.301,2.315.2.333,2.341,2.401,2.451,2.342,2.332,2.333, all P〈0.05）; The index of PaO2.heart rate, breathing in two groups were significant difference（t=2.232,2.31 1,2.3415,all P〈0.05）.Conclusion Ulinastatin may prevent the systemic injury by inflammatory response and improve the prognosis of ALI/ARDS.